April 6, 2016—The Centers for Medicare & Medicaid Services is giving drug manufacturers a three-month extension to begin calculating and reporting, in accordance with new federal regulations, the average manufacturer price for “5i” inhalation, infusion, instilled, implanted or injectable drugs that are not generally dispensed through retail community pharmacies.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)